Besides mutations in STAT3 and JAK1, oncogenic fusion genes, such as NFKB2-ROS1 and NFKB2-TYK2, also contribute to STAT3 activation in ALK-negative ALCL [49]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.